Positive Phase 3 results presented for Dupixent(®) (dupilumab) show significant
improvement on multiple measures of disease severity in adolescents with
moderate-to-severe atopic dermatitis
improvement on multiple measures of disease severity in adolescents with
moderate-to-severe atopic dermatitis
* Results on skin clearing, itch and certain quality of life measurements were
presented today as a late-breaking oral presentation at the 27(th) EADV
Congress
presented today as a late-breaking oral presentation at the 27(th) EADV
Congress
Detailed results from a pivotal Phase 3 trial showed Dupixent(®) (dupilumab) monotherapy demonstrated a significant improvement in signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients (12-17 years) with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. These data
were presented today at the 27(th) European Academy of Dermatology and
Venereology (EADV) Congress in Paris, France.
were presented today at the 27(th) European Academy of Dermatology and
Venereology (EADV) Congress in Paris, France.
There continues to be a significant unmet need for adolescents with moderate-to-
severe atopic dermatitis, whose disease cannot be controlled with topical
treatments. There are no systemic biologic medications approved for this patient
population. Dupixent is currently approved for use in certain adult patients
with moderate-to-severe atopic dermatitis in countries including the U.S.,
European Union, Canada and Japan. The results from this trial in adolescents
form the basis of regulatory submissions for patients ages 12 to 17.
severe atopic dermatitis, whose disease cannot be controlled with topical
treatments. There are no systemic biologic medications approved for this patient
population. Dupixent is currently approved for use in certain adult patients
with moderate-to-severe atopic dermatitis in countries including the U.S.,
European Union, Canada and Japan. The results from this trial in adolescents
form the basis of regulatory submissions for patients ages 12 to 17.
“Limited treatment options leave adolescents with uncontrolled moderate-to-
severe atopic dermatitis to cope with intense, unrelenting itch and skin
lesions,” said Amy S. Paller, M.D., Director of the Northwestern University Skin
Disease Research Center and principal investigator of the trial. “The results we
are presenting today show the potential for Dupixent in adolescents to not only
help clear the skin and reduce itching, but also improve certain aspects of
quality of life in adolescents who may be dealing with these unbearable
symptoms.”
severe atopic dermatitis to cope with intense, unrelenting itch and skin
lesions,” said Amy S. Paller, M.D., Director of the Northwestern University Skin
Disease Research Center and principal investigator of the trial. “The results we
are presenting today show the potential for Dupixent in adolescents to not only
help clear the skin and reduce itching, but also improve certain aspects of
quality of life in adolescents who may be dealing with these unbearable
symptoms.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.